Personalised medicine (PM) is a patient-specific approach to
treatment that integrates genetic, epigenomic, and clinical data. PM has the
potential to transform traditional medical practice by tailoring therapies to
individual genetic profiles. The significant advantages and limitations must be
carefully considered. Manufacturers are using drug repurposing,
biomarker-driven R&D, and collaborations with diagnostics and IT sectors.
Personalised medicine not only enhances therapeutic precision but also advances
preventive care through polygenic risk scores and early biomarker detection.
The integration of digital health tools, including wearables and telemedicine,
further supports patient-specific monitoring. Real-world examples, such as
FDA-approved targeted therapies and CAR-T cells, illustrate its transformative
potential. Innovations such as CRISPR-based interventions, AI-driven decision
support, and personalised vaccines are highlighted. Liquid biopsy, single-cell
omics, artificial intelligence, and healthcare digitalisation, further
supporting its implementation, are cutting-edge tools. The Quality by Design
(QbD) principles for safe, consistent, and effective production of personalised
3D-printed tablets have been explained. Critical material attributes (CMAs),
critical process parameters (CPPs), and critical quality attributes (CQAs)
together enable regulatory-compliant manufacturing by ensuring drug dosage
accuracy, content uniformity, dissolution control, and robust production
conditions. Beyond treatment, it raises ethical considerations related to data
privacy and equitable access. Although cost-intensive, it reduces long-term
healthcare burdens by minimising adverse reactions.
Author(s) Details
B. Navya Sree
Arya College of Pharmacy, India.
Saif Bin Salim
Arya College of Pharmacy, India.
Mohd Abdul Kareem
Arya College of Pharmacy, India.
M. Srikanth
Arya College of Pharmacy, India.
AVS Rajeswari
Department of Pharmaceutics, Arya College of Pharmacy, India.
Please see the book here :- https://doi.org/10.9734/bpi/msup/v1/6352
No comments:
Post a Comment